摘要
目的评价尘螨变应原特异性免疫治疗联合布地奈德/福莫特罗干粉吸入剂(BUD/FM)治疗中重度支气管哮喘的疗效。方法对2006年9月至2008年9月收治的93例中重度哮喘患者进行分析。按照治疗情况分为两组,对照治疗组46例为BUD/FM长期吸入治疗,联合治疗组47例为BUD/FM联合尘螨特异性免疫治疗。所有患者在治疗前和治疗后6、12、18及24个月进行观察,记录哮喘症状评分、肺功能,进行疗效及哮喘生活质量评估(AQLQ)的对比。结果联合治疗组的有效率明显优于对照治疗组(83.0%比65.2%,P<0.05);特别在治疗后期,联合治疗组肺功能FEV1%pred及呼气峰流速(PEF)的改善水平显著优于对照治疗组,AQLQ改善更明显,差异均有统计学意义(P<0.05)。结论特异性免疫治疗联合BUD/FM治疗中重度哮喘可显著改善哮喘症状和肺功能,依从性好且疗效持久,值得临床推广应用。
Objective To evaluate the efficacy of specific immunotherapy in combination with budesonide formoterol dry powder inhaler （BUD/FM） in the treatment of moderate to severe bronchial asthma.Methods The data of 93 patients with moderate to severe asthma from September 2006 to September 2008 were analyzed.46 cases who received BUD/FM therapy were recorded as a BUD/FM treatment group,and 47 cases who received BUD/FM and dust mite specific immunotherapy were recorded as a combination treatment group.After 6,12,18,and 24 months,asthma symptom scores,pulmonary function,effective rate,and scores of Asthma Quality of Life Questionnaire （AQLQ） were compared in the two treatment groups.Results Compared with the BUD/FM treatment group,the effective rate was significantly higher （83.0% vs.65.2%,P0.05）,the lung function improvements in FEV1%pred and expiratory peak flow were more significant in the latter period of treatment,and AQLQ scores improved more significantly after 24 months’ treatment in the combination treatment group.Conclusion For patients with moderate to severe asthma,specific immunotherapy in combination with BUD/FM can improve asthma symptoms and lung function with good compliance and long lasting efficacy.
出处
《中国呼吸与危重监护杂志》
CAS
2010年第4期374-377,共4页
Chinese Journal of Respiratory and Critical Care Medicine
